NCT04747431: An ongoing trial by Passage Bio, Inc.
This trial is ongoing. It must report results 3 years, 11 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04747431 |
|---|---|
| Title | A Phase 1b Open-Label, Multicenter, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacodynamic Effects of a Single Dose of PBFT02 Delivered Into the ICM of Adults With FTD and Mutations in the GRN or C9ORF72 Genes |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 14, 2021 |
| Completion date | Aug. 31, 2028 |
| Required reporting date | Aug. 31, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Sept. 4, 2025 |
| Days late | None |